1 Rare Genomic Copy Number Variants Implicate New Candidate Genes for Bicuspid Aortic 2 Valve

51 [&] Complete lists of EBAV and BAVCon Investigators are provided in the Acknowledgments.

Abstract

Author Summary

It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.10.23.23297397;](https://doi.org/10.1101/2023.10.23.23297397) this version posted October 24, 2023. The copyright holder for this preprint

Introduction

 Copy number variants (CNVs) have been implicated as causes or modifiers of many human diseases [1]. Specifically, large genomic CNVs are significantly enriched in cohorts with developmental delay or congenital abnormalities, and the severity of phenotypes has been correlated with the burden of rare CNVs [2]. These observations show that large, rare, *de novo* CNVs are likely to be pathogenic and can exert clinically relevant effects on disease pathogenesis [3-4].

 Congenital heart disease (CHD) has a worldwide prevalence of 8.2 per 1000 live births [5]. CNVs have been implicated in both syndromic and non-syndromic forms of CHD [6-10]. The pathogenicity and penetrance of CNVs was initially established for clinical syndromes such as velocardiofacial syndrome, Turner syndrome, or Williams–Beuren syndrome, which involve chromosomal or megabase scale duplications or deletions, but has since been expanded to include additional CHD subtypes [10]. CNVs contribute to 10% of all CHD cases and up to 25% of cases with extracardiac anomalies or other syndromic features [11]. The role of pathogenic CNVs affecting genes that are known to cause CHD when mutated, such as *GATA4* and *TBX1*, has been established [12]. Furthermore, population-level analysis has consistently demonstrated an increased burden of CHD in carriers of CNVs at specific genomic hotspots compared to controls, displaying the pathogenic potential of rare or *de novo* CNVs [12-14]. Bicuspid Aortic Valve (BAV) is the most common congenital heart malformation with a 99 population prevalence of $0.5 - 2\%$ [15]. BAV predisposes to aortic valve stenosis and thoracic aortic aneurysms and is associated with other left ventricular outflow tract lesions such as mitral valve disease and coarctation [16]. The high heritability of BAV was demonstrated in first- and

 second-degree relatives, who are more than ten times more likely to be diagnosed with BAV compared to matched controls [17]. BAV can occur as an isolated congenital lesion or as part of a clinical syndrome. For example, the prevalence of BAV is increased in Velocardiofacial, Loeys-Dietz, Kabuki, and Turner syndromes. Pathogenic variants of several genes are implicated in familial non-syndromic BAV, which is typically inherited as an autosomal dominant trait with reduced penetrance and variable expressivity. There is strong cumulative evidence that *GATA4, GATA6, NOTCH1, ROBO4, SMAD4*, *MUC4*, and *SMAD6* each contribute to a small percentage of non-syndromic BAV cases. Phenotypic expression of BAV disease ranges from incidental discovery in late adulthood to neonatal or childhood onset of complications. In comparison to patients with later disease onset, younger BAV cohorts tend to present with syndromic features or complex congenital malformations that are more likely to have a genetic cause, thereby increasing the power of association studies to discover clinically relevant CNVs [18]. Recently, we identified recurrent rare CNVs that were enriched for cardiac developmental genes in a young cohort with early-onset thoracic aortic aneurysms or acute aortic dissections [19].

 We hypothesize that large rare genomic CNVs contribute to early onset complications of BAV. Consistent with previous observations, we predict that the burden and penetrance of rare CNVs will be increased in individuals with early onset disease when compared to elderly sporadic BAV cases and population controls. Identification of novel pathogenic CNVs can provide new insights into the genetic complexity of BAV and may be useful for personalized risk stratification or clinical guidance based on the specific recurrent CNV [20]. Therefore, we set out to describe the burden and penetrance of rare CNVs in a young cohort with early onset complications of BAV disease (EBAV).

Materials and Methods

 The study protocol was approved by the Committee for the Protection of Human Subjects at the University of Texas Health Science Center at Houston (HSC-MS-11-0185). After written informed consent, we enrolled 272 probands of European ancestry with early onset BAV disease (EBAV), which we defined as individuals with BAV who were under the age of 30 at the time of first clinical event. Clinical events were defined as aortic replacement, aortic valve surgery, 132 aortic dissection, moderate or severe aortic stenosis or aortic regurgitation, large aneurysm $(Z >$ 4.5), or intervention for BAV-related conditions. Those with hypoplastic left heart, known genetic mutations, genetic syndromes, or complex congenital heart disease were excluded. Affected and unaffected family members of probands were included in this cohort for a total of 544 individuals in 293 families (26 trios and 16 multiplex families). Samples were collected and genotyped similar to our previous study [21]. For comparison, we analyzed a cohort of older individuals of European ancestry with sporadic BAV disease selected from the International BAV Consortium (Table 1) [22].

-
-

Table 1. Summary of Case Cohorts.

143 Cohort: name of case cohort; EBAV: family-based cohort selected for early onset complications of bicuspid aortic
144 valve (BAV); BAVGWAS: unrelated probands with sporadic BAV disease. Source: origin of genotypes; Arra 144 valve (BAV); BAVGWAS: unrelated probands with sporadic BAV disease. Source: origin of genotypes; Array: microarray used for genotyping. microarray used for genotyping. Phenotypes were derived from record review with confirmation of image data whenever possible [23-24]. The computational pipeline for CNV analysis of Illumina single nucleotide

polymorphism (SNP) array data included three independent CNV detection algorithms (Fig 1).

It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.10.23.23297397;](https://doi.org/10.1101/2023.10.23.23297397) this version posted October 24, 2023. The copyright holder for this preprint

150

Fig 1. Overview of Pipeline for CNV Identification and Validation.
152 SNP, single nucleotide polymorphism. OC, Quality control. CNV, copy number varia 152 SNP, single nucleotide polymorphism. QC, Quality control. CNV, copy number variant. The software and algorithms used for the analysis are provided in boxes to the left of the corresponding steps. Illumina raw s 153 algorithms used for the analysis are provided in boxes to the left of the corresponding steps. Illumina raw signal
154 intensity data was trimmed and exported using GenomeStudio. The intensity data was then analyzed wi 154 intensity data was trimmed and exported using GenomeStudio. The intensity data was then analyzed with three 155 different CNV calling algorithms (PennCNV [25], cnvPartition, and QuantiSNP [26]) to generate initial CNV calls
156 and sample-level statistics. Sample-level quality control analysis was performed using PennCNV. PLINK 156 and sample-level statistics. Sample-level quality control analysis was performed using PennCNV. PLINK [27] toolset was used to define CNV regions from initial CNV calls for subsequent burden testing, enrichment studi toolset was used to define CNV regions from initial CNV calls for subsequent burden testing, enrichment studies, 158 and replication studies. The initial CNV calls were individually screened for CNVs intersecting with candidate loci,
159 which we defined as genes implicated in bicuspid aortic valve disease and those discovered in our 159 which we defined as genes implicated in bicuspid aortic valve disease and those discovered in our enrichment 160 studies. CNVs of interest were then validated in GenomeStudio. studies. CNVs of interest were then validated in GenomeStudio.

- 161
- 162 GenomeStudio was used to exclude samples with indeterminate sex or more than 5%
- 163 missing genotypes, and single nucleotide polymorphisms (SNPs) with GenTrain = 0. Principal
- 164 component analysis was used to remove outliers that did not cluster with European ancestry.
- 165 Only SNPs common to all microarray platforms were included.

 Three independent algorithms (PennCNV, cnvPartition, and QuantiSNP) were used to generate CNV calls and sample-level quality statistics from SNP intensity data. PennCNV and QuantiSNP were run on Unix clusters and cnvPartition data were exported from GenomeStudio. The analysis was run using default configurations. PennCNV was used to generate QC data and remove CNV calls that intersect with polymorphic genomic regions. Samples that met any of the following criteria were excluded: 172 standard deviation of the LogR ratio (obtained from PennCNV) > 0.35 or number of CNVs > 2 standard deviations above the mean for each data set. CNV calls less than 20 kilobase pairs 174 and/or spanned by less than 6 SNP probes were excluded. The overlap function for rare CNVs in PLINK was used to construct CNV regions (CNVRs) and adjacent regions were merged using PennCNV. LogR ratio (LRR) and B allele frequency (BAF) data at CNVRs and calls of interest were visualized in GenomeStudio for validation. For segregation analysis, GenomeStudio was used to determine the presence of CNVs in relatives. A total of 22,014 unselected control Illumina Genotypes obtained from the Database of Genotypes and Phenotypes were analyzed using identical methods (Table in S1Table). Cohorts were paired as follows for case-control analysis based on the concordance of sample-level quality control statistics (mean number of CNV calls and mean standard deviation of the LogR Ratio): EBAV and WLS, BAVGWAS and HRS. PLINK was used to catalog CNV calls and perform burden and enrichment studies. Case - control burden tests were restricted to large (250 - 5000 kilobase pairs), rare (occurring in less 187 than 1 in 1000 samples; total of cases and controls), and validated CNV calls in EBAV probands. Genome Reference Consortium Human Build 37 [28] was used for CNV annotation.

¹⁸⁹ **Results**

 Compared to BAVGWAS probands, EBAV probands were significantly younger at diagnosis, had more frequent co-existing congenital heart and vascular lesions, and underwent more frequent valve or aortic operations. A phenotype summary of the EBAV and BAVGWAS Cohorts is provided in Table 2. 194

-
-

195 **Table 2. Characteristics of EBAV and BAVGWAS Probands.**

196

197 N: number of cases; \pm , standard deviation; TAA, thoracic aortic aneurysm; AR: aortic regurgitation; AS, aortic stenosis; Other Lesions, other congenital heart malformations (primarily coarctation or ventricular sept 198 stenosis; Other Lesions, other congenital heart malformations (primarily coarctation or ventricular septal defect). We had phenotype information for 279 EBAV probands but did not have access to genotype information for had phenotype information for 279 EBAV probands but did not have access to genotype information for all samples. 200 201 CNV analysis is summarized in Table 3. The percentages of individuals with large and 202 rare CNV regions were relatively consistent throughout datasets. The prevalence of large and 203 rare CNVs, specifically large genomic deletions, was increased in EBAV cases compared to

204 controls (Table S2).

206

205 **Table 3. Summary of CNV Calls for EBAV Cohort.**

207 Large: CNV regions between 250 Kb and 5 Mb in length. Rare: occur in fewer than 1 in 1000 individuals; Rate:
208 number of CNVs per individual: Prop: proportion of samples with one or more CNVs: TOT: total length of al

208 number of CNVs per individual; Prop: proportion of samples with one or more CNVs; TOT: total length of all 209 CNVs in kilobases; AVG: mean CNV length. p^E , p-value for EBAV cohort in respective category. p^B , p-v

CNVs in kilobases; AVG: mean CNV length. p^E , *p*-value for EBAV cohort in respective category. p^B , *p*-value for

210 BAVGWAS in respective category. Tests are 1-sided with 100,000 permutations. A subset of CNV calls from the
211 BBAV and BAVGWAS datasets were validated by examining GenomeStudio plots. In total. 125/347 (36%) of 211 EBAV and BAVGWAS datasets were validated by examining GenomeStudio plots. In total, 125/347 (36%) of 212 EBAV and 289/600 (48%) of BAVGWAS CNVs were validated. EBAV and 289/600 (48%) of BAVGWAS CNVs were validated. 213 There were 34 large (>250 Kb), rare (<1:1000 in dbGAP controls) CNV regions that involved protein-coding genes in EBAV cases (Table S3). Seven of these genic CNVs were 216 enriched in EBAV cases compared to WLS controls with a genome-wide adjusted empiric $P <$ 0.05. These CNVs included the genes *PCP4*, *DSCAM*, *MIR4760*, and *DSCAM-AS1* in 21q22 and *GATA4*, *C8orf49*, *NEIL2*, *FDFT1*, and *CTSB* in 8p23. Large duplications involving the Velocardiofacial (VCFS) region in 22q11.2 and 1q21.1 microduplications were also enriched in EBAV cases (Table S4). The overall burden of large, rare, genic CNVs was not different between EBAV cases and WLS controls. However, the burden of large, rare genic CNVs intersecting with genes known to cause BAV when mutated or implicated in syndromic BAV was significantly increased in EBAV cases (Table 4).

225

224 **Table 4. Burden Testing of Rare EBAV CNVs.**

	EBAV		WLS			
	Calls	Rate	Calls	Rate	RR	D
Genic	28	0.8	1151	0.65		0.23
Deletions		$3.8x10^{-2}$	439	$4.6x10^{-2}$	0.81	0.78
BAV		$1.0x10^{-2}$		$1.1x10^{-4}$	97	$1.1x10^{-3}$
Total	34	$\overline{}$	1443	$\overline{}$	$\overline{}$	-

²²⁶ Calls: total number of CNVs that met the specified criteria. Rate: number of CNVs per individual; RR: relative risk;
227 P: p-value; Genic; CNVs that intersect with genes; BAV: CNVs that intersect with genes that are k *P*: p-value; Genic; CNVs that intersect with genes; BAV: CNVs that intersect with genes that are known to cause bicuspid aortic valve (BAV) when mutated or implicated in syndromic BAV. Total: total number of large, rare CNVs or CNVRs. Tests are 2-sided using 100,000 permutations. $\frac{228}{229}$
230 231 We also scrutinized genomic regions that are implicated in CHD by careful analysis of 232 data from individual CNV algorithms to detect subtle copy number alterations. We identified 233 additional rare EBAV CNVs that intersect with CHD candidate genes *CELSR1*, *GJA5*, *RAF1*, 234 *LTBP1, KIF1A*, *MYH11*, *MAPK3*, *TTN*, and the VCFS region in 22q11.2. We detected additional 235 *GATA4* and *DSCAM* CNVs in multiplex families. These CNVs were enriched in EBAV cases 236 compared to WLS controls (Table 5).

237 **Table 5. CNVs Affecting Congenital Heart Disease Genes in EBAV Cohort.**

238 Region: coordinates corresponding to the minimum overlap region of CNVs; Genes: cardio-
239 developmental candidate genes in the region. Case: number of large and rare CNVs in EBAV

239 developmental candidate genes in the region. Case: number of large and rare CNVs in EBAV cases that intersect with region of intersect with region of interest. Control: number of CNVs in WLS cohort that intersect with 240 with region of interest. Control: number of CNVs in WLS cohort that intersect with region of interest. OR: odds
241 ratio: 95% CI, 95% confidence interval for respective odds ratio. ratio; 95% CI, 95% confidence interval for respective odds ratio.

242

243 Next, we attempted to replicate our observations by identifying CNVs in the BAVGWAS

244 dataset that overlapped with rare EBAV CNVs. We found that large duplications involving

245 *SOX7* and *GATA4* in 8p23 and the VCFS region in 22q11.2 were also significantly enriched in

246 BAVGWAS cases compared to HRS controls (Table 6, Table S6 and S7).

²⁴⁷

248	Table 6. CNVs Affecting Congenital Heart Disease Genes in BAVGWAS Cohort.						
	Region	Genes	Case	Control	OR	95% CI	
	Chr3:29993977-31273870	<i>TGFBR2</i>	1	θ	5.6	0.23 to 138	
	Chr9:101861767-102092282	TGFBR1	1	θ	5.6	0.23 to 138	
	Chr21:41577819-41842252	<i>DSCAM</i>	2		3.7	0.34 to 41	
	Chr22:46924254-46931077	CELSR1	3		5.6	0.58 to 54	
	Chr2:111404636-11310378	TMEM87B, FBLN7	3	2	2.8	0.47 to 17	
	Chr8:11385469-11821835	GATA4	8		15	1.9 to 120	
	Chr12:7918339-8130958	NANOG	10	2	9.4	2.1 to 43	
	Chr2:147166377-147308112	GJA5	$\overline{4}$	10	0.75	0.23 to 2.4	
	Chr16:29664753-30199713	MAPK3	3	15	0.37	0.11 to 1.3	
	Chr22:19000000-22000000	TBX1, CRKL	18	11	3.1	1.4 to 6.5	
	Chr2:32689829-33299434	<i>LTBP1</i>	9	22	0.76	0.35 to 1.7	
	Chr16:15240816-16281154	<i>MYH11</i>	13	27	0.90	$0.46 \text{ to } 1.7$	
	Chr2:241640262-241689833	KIF1A	13	30	0.81	$0.42 \text{ to } 1.6$	

249 Region: coordinates corresponding to the minimum overlap region of CNVs; Genes: cardio-
250 developmental candidate genes in the region. Case: number of large and rare CNVs in BAV

250 developmental candidate genes in the region. Case: number of large and rare CNVs in BAVGWAS cases that
251 intersect with region of interest. Control: number of CNVs in HRS cohort that intersect with region of interest

intersect with region of interest. Control: number of CNVs in HRS cohort that intersect with region of interest. OR:

- odds ratio; 95% CI, 95% confidence interval for respective odds ratio. 253
-

It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.10.23.23297397;](https://doi.org/10.1101/2023.10.23.23297397) this version posted October 24, 2023. The copyright holder for this preprint

- CNVs intersecting with *GATA4* and *DSCAM* significantly overlapped between EBAV
- and BAVGWAS datasets (Fig 2). On average, the *GATA4* CNVs were larger in the BAVGWAS
- dataset while the *DSCAM* CNVs were larger in the EBAV dataset.

-
- EBAV and are rare or absent in controls (Table S5). *NANOG* and *NIBPL* are essential for early

- heart development, and mutation of *NIBPL* causes Cornelia-de Lange syndrome with a spectrum of congenital heart malformations including BAV.
- We also identified 21 very large genomic CNVs more than 5 Mb in length in the
- BAVGWAS dataset. Analysis of GenomeStudio data showed that most of these were mosaic
- loss of heterozygosity regions or duplications. Nine were large germline chromosome-scale
- aberrations, including two cases of trisomy 21 (Table S8). We did not identify any large X
- chromosome copy variants that may be consistent with Turner syndrome. There were no
- megabase-scale copy number variants in the EBAV dataset.

Pedigree analysis showed that several CNVs involving *CELSR1*, *LTBP1*, *KIF1A*, *GATA4*,

and *DSCAM* segregate with BAV in EBAV families (Table S9). CNV carriers tended to present

due to moderate or severe aortic regurgitation requiring valvular surgery. One proband had aortic

coarctation. The youngest age at presentation was 13 years. There were no sex differences in

presentation between CNV carriers.

Discussion

 We identified large, rare, and likely pathogenic CNVs in almost 10% of EBAV probands 292 that are enriched in genes that cause BAV when mutated. The percentage of EBAV cases with likely pathogenic CNVs is similar to our previous observations in a cohort with early onset TAD [30]. Enrichment of CNVs involving *GATA4* and *DSCAM* in EBAV cases replicated in two additional BAV datasets and thousands of unselected control genotypes. This analysis provides compelling evidence that rare CNVs collectively cause more BAV cases than any single mutated gene.

congenital heart lesions is increased in individuals with velocardiofacial syndrome who have

22q1.2 deletions and a common 12p13.31 duplication involving the *SLC2A3* gene. The *SLC2A3*

CNV likely functions as a modifier of the cardiac phenotype associated with 22q11 deletion

syndrome, exemplifying a "two-hit" model [40].

 We also identified recurrent rare CNVs of specific dosage-sensitive regions that affect cardiac developmental genes and are implicated in non-syndromic CHD. Recurrent 1q21.1 distal deletions encompassing *GJA5*, the gene encoding Connexin-40, are associated with CHD lesions including BAV. A study of 807 TOF cases showed significant enrichment of small duplications spanning the *GJA5* gene, providing compelling evidence that it acted as the primary candidate gene, supporting the association of *GJA5* and CHD [31]. Additionally, cardiac abnormalities

Acknowledgments

References

- 1. Zhang F, Gu W, Hurles ME, Lupski JR. Copy number variation in human health, disease, and
- evolution. Annual review of genomics and human genetics. 2009;10:451.
- 2. Cooper GM, Coe BP, Girirajan S, Rosenfeld JA, Vu TH, Baker C, Williams C, Stalker H,
- Hamid R, Hannig V, Abdel-Hamid H. A copy number variation morbidity map of developmental
- delay. Nature genetics. 2011 Sep;43(9):838-46.
- 3. Girirajan S, Rosenfeld JA, Coe BP, Parikh S, Friedman N, Goldstein A, Filipink RA,
- McConnell JS, Angle B, Meschino WS, Nezarati MM. Phenotypic heterogeneity of genomic
- disorders and rare copy-number variants. New England Journal of Medicine. 2012 Oct 4;367(14):1321-31.
- 4. Kaufman L, Ayub M, Vincent JB. The genetic basis of non-syndromic intellectual disability: a review. Journal of neurodevelopmental disorders. 2010 Dec;2(4):182-209.
- 5. Liu, Y., Chen, S., Zühlke, L., Black, G., Choy, M. K., Li, N., & Keavney, B. (2019). Global
- birth prevalence of congenital heart defects 1970–2017: Updated systematic review and meta-
- analysis of 260 studies. International Journal of Epidemiology, 48(42), 455–463.
- 6. Hitz MP, Lemieux-Perreault LP, Marshall C, Feroz-Zada Y, Davies R, Yang SW, Lionel AC,
- D'Amours G, Lemyre E, Cullum R, Bigras JL. Rare copy number variants contribute to
- congenital left-sided heart disease.
- 7. Warburton D, Ronemus M, Kline J, Jobanputra V, Williams I, Anyane-Yeboa K, Chung W,
- Yu L, Wong N, Awad D, Yu CY. The contribution of de novo and rare inherited copy number
- changes to congenital heart disease in an unselected sample of children with conotruncal defects
- or hypoplastic left heart disease. Human genetics. 2014 Jan;133:11-27.
- 8. Silversides CK, Lionel AC, Costain G, Merico D, Migita O, Liu B, Yuen T, Rickaby J,
- Thiruvahindrapuram B, Marshall CR, Scherer SW. Rare copy number variations in adults with
- tetralogy of Fallot implicate novel risk gene pathways.
- 9. Ware SM, Jefferies JL. New genetic insights into congenital heart disease. Journal of clinical & experimental cardiology. 2012 Jun 6.
- 10. Sørensen KM, El‐Segaier M, Fernlund E, Errami A, Bouvagnet P, Nehme N, Steensberg J,
- Hjortdal V, Soller M, Behjati M, Werge T. Screening of congenital heart disease patients using
- multiplex ligation‐dependent probe amplification: Early diagnosis of syndromic patients.
- American journal of medical genetics Part A. 2012 Apr;158(4):720-5.
- 11. Lander J, Ware SM. Copy number variation in congenital heart defects. Current Genetic
- Medicine Reports. 2014 Sep;2:168-78.

- 12. Tomita-Mitchell A, Mahnke DK, Struble CA, Tuffnell ME, Stamm KD, Hidestrand M,
- Harris SE, Goetsch MA, Simpson PM, Bick DP, Broeckel U. Human gene copy number spectra
- analysis in congenital heart malformations. Physiological genomics. 2012 May 1;44(9):518-41.

13. Kim DS, Kim JH, Burt AA, Crosslin DR, Burnham N, Kim CE, McDonald-McGinn DM,

- Zackai EH, Nicolson SC, Spray TL, Stanaway IB. Burden of potentially pathologic copy number
- variants is higher in children with isolated congenital heart disease and significantly impairs
- covariate-adjusted transplant-free survival. The Journal of thoracic and cardiovascular surgery. 2016 Apr 1;151(4):1147-51.
- 14. Soemedi R, Wilson IJ, Bentham J, Darlay R, Töpf A, Zelenika D, Cosgrove C, Setchfield K,
- Thornborough C, Granados-Riveron J, Blue GM. Contribution of global rare copy-number
- variants to the risk of sporadic congenital heart disease. The American Journal of Human
- Genetics. 2012 Sep 7;91(3):489-501.
- 15. Chandra S, Lang RM, Nicolarsen J, Gayat E, Spencer KT, Mor-Avi V, Hofmann Bowman
- MA. Bicuspid aortic valve: inter-racial difference in frequency and aortic dimensions. JACC:
- Cardiovascular Imaging. 2012 Oct;5(10):981-9.
- 16. Michelena HI, Prakash SK, Della Corte A, Bissell MM, Anavekar N, Mathieu P, Bossé Y,
- Limongelli G, Bossone E, Benson DW, Lancellotti P. Bicuspid aortic valve: identifying
- knowledge gaps and rising to the challenge from the International Bicuspid Aortic Valve
- Consortium (BAVCon). Circulation. 2014 Jun 24;129(25):2691-704.
- 17. Glotzbach JP, Hanson HA, Tonna JE, Horns JJ, McCarty Allen C, Presson AP, Griffin CL,
- Zak M, Sharma V, Tristani-Firouzi M, Selzman CH. Familial Associations of Prevalence and
- Cause-Specific Mortality for Thoracic Aortic Disease and Bicuspid Aortic Valve in a Large-
- Population Database. Circulation. 2023 Jun 15.
- 18. Prakash SK, Yetman A, Bissell MM, Kim YY, Michelena H, Hui DS, Caffarelli A,
- Andreassi MG, Foffa I, Jennings J, Citro R. Recurrent genomic copy number variants implicate
- new candidate genes for early onset bicuspid aortic valve disease. Journal of the American
- College of Cardiology. 2019 Mar 12;73(9S1):620-.
- 19. Prakash S, Kuang SQ, GenTAC Registry Investigators, Regalado E, Guo D, Milewicz D.
- Recurrent rare genomic copy number variants and bicuspid aortic valve are enriched in early
- onset thoracic aortic aneurysms and dissections. PloS one. 2016 Apr 19;11(4):e0153543.
- 20. Balistreri CR, Cavarretta E, Sciarretta S, Frati G. Light on the molecular and cellular
- mechanisms of bicuspid aortic valve to unveil phenotypic heterogeneity. Journal of Molecular
- and Cellular Cardiology. 2019;133: 113–114. Doi:10.1016/j.yjmcc.2019.06.004.
- 21. Prakash, S.K., LeMaire, S.A., Guo, D.C., Russell, L., Regalado, E.S., Golabbakhsh, H.,
- Johnson, R.J., Safi, H.J., Estrera, A.L., Coselli, J.S. and Bray, M.S., 2010. Rare copy number -
- variants disrupt genes regulating vascular smooth muscle cell adhesion and contractility in
- sporadic thoracic aortic aneurysms and dissections. *The American Journal of Human*
- *Genetics*, *87*(6), pp.743-756.

- 22. Prakash SK, Bossé Y, Muehlschlegel JD, Michelena HI, Limongelli G, Della Corte A,
- Pluchinotta FR, Russo MG, Evangelista A, Benson DW, Body SC. A roadmap to investigate the
- genetic basis of bicuspid aortic valve and its complications: insights from the International
- BAVCon (Bicuspid Aortic Valve Consortium). Journal of the American College of Cardiology.
- 2014 Aug 26;64(8):832-9.
-
- 23. PA Harris, R Taylor, R Thielke, J Payne, N Gonzalez, JG. Conde. Research electronic data capture (REDCap) – A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009 Apr;42(2):377-81.
- 24. PA Harris, R Taylor, BL Minor, V Elliott, M Fernandez, L O'Neal, L McLeod, G Delacqua,
- F Delacqua, J Kirby, SN Duda, REDCap Consortium, The REDCap consortium. Building an
- international community of software partners. J Biomed Inform. 2019 May 9 [doi:
- 10.1016/j.jbi.2019.103208].
- 25. Wang K, Li M, Hadley D, Liu R, Glessner J, Grant SF, Hakonarson H, Bucan M. PennCNV:
- an integrated hidden Markov model designed for high-resolution copy number variation
- detection in whole-genome SNP genotyping data. Genome research. 2007 Nov 1;17(11):1665- 74.
- 26. Colella S, Yau C, Taylor JM, Mirza G, Butler H, Clouston P, Bassett AS, Seller A, Holmes
- CC, Ragoussis J. QuantiSNP: an Objective Bayes Hidden-Markov Model to detect and
- accurately map copy number variation using SNP genotyping data. Nucleic acids research. 2007 Mar 1;35(6):2013-25.
- 27. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, De
- Bakker PI, Daly MJ, Sham PC. PLINK: a tool set for whole-genome association and population-
- based linkage analyses. The American journal of human genetics. 2007 Sep 1;81(3):559-75.
- 28. Church DM, Schneider VA, Graves T, Auger K, Cunningham F, Bouk N, Chen HC,
- Agarwala R, McLaren WM, Ritchie GR, Albracht D. Modernizing reference genome assemblies. PLoS biology. 2011 Jul 5;9(7):e1001091.
- 29. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, Haussler D. The
- human genome browser at UCSC. Genome research. 2002 Jun 1;12(6):996-1006.
- 30. Prakash S, Kuang SQ, GenTAC Registry Investigators, Regalado E, Guo D, Milewicz D.
- Recurrent rare genomic copy number variants and bicuspid aortic valve are enriched in early
- onset thoracic aortic aneurysms and dissections. PloS one. 2016 Apr 19;11(4):e0153543.
- 31. Durocher, D., Charron, F., Warren, R., Schwartz, R. J., Nemer, M. The cardiac transcription factors Nkx2-5 and GATA-4 are mutual cofactors. EMBO J. 16: 5687-5696, 1997.
- 32. Tremblay M, Sanchez-Ferras O, Bouchard M. GATA transcription factors in development and disease. Development. 2018 Oct 15;145(20):dev164384.
- 33. McCulley DJ, Black BL. Transcription factor pathways and congenital heart disease. Current topics in developmental biology. 2012 Jan 1;100:253-77.

- 34. Alonso‐Montes C, Martín M, Martínez‐Arias L, Coto E, Naves‐Díaz M, Morís C, Cannata‐
- Andía JB, Rodríguez I. Variants in cardiac GATA genes associated with bicuspid aortic valve.
- European journal of clinical investigation. 2018 Dec;48(12):e13027.
- 35. Pehlivan T, Pober BR, Brueckner M, Garrett S, Slaugh R, Van Rheeden R, Wilson DB,
- Watson MS, Hing AV. GATA4 haploinsufficiency in patients with interstitial deletion of
- chromosome region 8p23. 1 and congenital heart disease. American journal of medical genetics.
- 501 1999 Mar 19;83(3):201-6.
- 36. Li RG, Xu YJ, Wang J, Liu XY, Yuan F, Huang RT, Xue S, Li L, Liu H, Li YJ, Qu XK.
- GATA4 loss-of-function mutation and the congenitally bicuspid aortic valve. The American journal of cardiology. 2018 Feb.
- 37. Glessner JT, Bick AG, Ito K, Homsy JG, Rodriguez-Murillo L, Fromer M, Mazaika E,
- Vardarajan B, Italia M, Leipzig J, DePalma SR. Increased frequency of de novo copy number
- variants in congenital heart disease by integrative analysis of single nucleotide polymorphism
- array and exome sequence data. Circulation research. 2014 Oct 24;115(10):884-96.
- 38. Zogopoulos G, Ha KC, Naqib F, Moore S, Kim H, Montpetit A, Robidoux F, Laflamme P,
- Cotterchio M, Greenwood C, Scherer SW. Germ-line DNA copy number variation frequencies in
- a large North American population. Human genetics. 2007 Nov;122:345-53.
- 39. Yu S, Zhou XG, Fiedler SD, Brawner SJ, Joyce JM, Liu HY. Cardiac defects are infrequent
- findings in individuals with 8p23. 1 genomic duplications containing GATA4. Circulation:
- Cardiovascular Genetics. 2011 Dec;4(6):620-5.
- 40. Mlynarski EE, Sheridan MB, Xie M, Guo T, Racedo SE, McDonald-McGinn DM, Gai X,
- Chow EW, Vorstman J, Swillen A, Devriendt K. Copy-number variation of the glucose
- transporter gene SLC2A3 and congenital heart defects in the 22q11. 2 deletion syndrome. The
- American Journal of Human Genetics. 2015 May 7;96(5):753-64.
- 41. Freeman SB, Taft LF, Dooley KJ, Allran K, Sherman SL, Hassold TJ, Khoury MJ, Saker
- 520 DM. Population-based study of congenital heart defects in Down syndrome. American journal of
- medical genetics. 1998 Nov 16;80(3):213-7.
- 42. Paladini D, Tartaglione A, Agangi A, Teodoro A, Forleo F, Borghese A, Martinelli P. The
- association between congenital heart disease and Down syndrome in prenatal life. Ultrasound in
- Obstetrics and Gynecology. 2000 Feb;15(2):104-8.
- 43. Laursen HB. Congenital heart disease in Down's syndrome. Heart. 1976 Jan 1;38(1):32-8.
- 44. Kosaki R, Kosaki K, Matsushima K, Mitsui N, Matsumoto N, Ohashi H. Refining
- 527 chromosomal region critical for Down syndrome-related heart defects with a case of cryptic 21q22. 2 duplication. Congenital anomalies. 2005 Jun;45(2):62-4.
- 45. Grossman TR, Gamliel A, Wessells RJ, Taghli-Lamallem O, Jepsen K, Ocorr K, Korenberg
- JR, Peterson KL, Rosenfeld MG, Bodmer R, Bier E. Over-expression of DSCAM and COL6A2
- cooperatively generates congenital heart defects. PLoS genetics. 2011 Nov 3;7(11):e1002344.

- 46. Gu H, Smith FC, Taffet SM, Delmar M. High incidence of cardiac malformations in
- connexin40-deficient mice. Circulation research. 2003 Aug 8;93(3):201-6.
- 47. Theis JL, Niaz T, Sundsbak RS, Fogarty ZC, Bamlet WR, Hagler DJ, et al. CELSR1 Risk
- Alleles in Familial Bicuspid Aortic Valve and Hypoplastic Left Heart Syndrome. Circ: Genomic and Precision Medicine. 2022;15. doi:10.1161/CIRCGEN.121.003523.
-
- 48. Pottie L, Adamo CS, Beyens A, Lütke S, Tapaneeyaphan P, De Clercq A, et al. Bi-allelic premature truncating variants in LTBP1 cause cutis laxa syndrome. The American Journal of
- Human Genetics. 2021;108: 1095–1114. doi:10.1016/j.ajhg.2021.04.016.
- 49. Akasaka T, Ocorr K, Lin L, Vogler G, Bodmer R, Grossfeld P. Overexpression of Kif1A in
- the Developing Drosophila Heart Causes Valvar and Contractility Defects: Implications for
- Human Congenital Heart Disease. JCDD. 2020;7: 22. doi:10.3390/jcdd7020022.
- 50. Pannu H, Tran-Fadulu V, Papke CL, Scherer S, Liu Y, Presley C, et al. MYH11 mutations
- result in a distinct vascular pathology driven by insulin-like growth factor 1 and angiotensin II.
- Human Molecular Genetics. 2007;16: 2453–2462. doi:10.1093/hmg/ddm201.
- 51. Herman DS, Lam L, Taylor MRG, Wang L, Teekakirikul P, Christodoulou D,
- et.al. Truncations of titin causing dilated cardiomyopathy. New England Journal of Medicine.
- 2012;366: 619-628. doi: 10.1056/NEJMoa1110186

⁵⁴⁹ **Supplemental Data**

550

S1 Table. Summary of Control Cohorts. Cohort, name of control cohort. Study, study from which genotypes were obtained. Samples, number of control samples in each dataset. Accession, Database of Genotypes and Phenotypes accession number. Microarray, Illumina microarray used for genotyping.

551 **S2 Table. Comprehensive CNV Summary.**EBAV, EBAV Cohort including cases and unaffected family members.
552 BAVGWAS, BAVGWAS cohort. WLS, WLS cohort. HRS, HRS cohort. PennCNV, number of CNV calls detected 552 BAVGWAS, BAVGWAS cohort. WLS, WLS cohort. HRS, HRS cohort. PennCNV, number of CNV calls detected
553 by PennCNV algorithm after quality control. cnvPartition, number of CNV calls detected by cnvPartition algorithm 553 by PennCNV algorithm after quality control. cnvPartition, number of CNV calls detected by cnvPartition algorithm
554 after quality control. QuantiSNP, number of CNVs detected by QuantiSNP algorithm after quality contro 554 after quality control. QuantiSNP, number of CNVs detected by QuantiSNP algorithm after quality control. Merged,
555 number of CNV regions after merging initial calls. Deletions, number of CNV regions that are deletions 555 number of CNV regions after merging initial calls. Deletions, number of CNV regions that are deletions. >5 MB,
556 number of CNV regions that are larger than 5 megabases. Rare, number of large (> 250 kilobases and less 556 number of CNV regions that are larger than 5 megabases. Rare, number of large (> 250 kilobases and less than 5
557 megabases) CNV regions that occur in less than 1 in 1000 samples based on case-control cohort pairs (EB 557 megabases) CNV regions that occur in less than 1 in 1000 samples based on case-control cohort pairs (EBAV and 558 WLS; BAVGWAS and HRS). R. Del., number of large, rare deletions. All values reflect the total CNV calls 558 WLS; BAVGWAS and HRS). R. Del., number of large, rare deletions. All values reflect the total CNV calls and regions prior to validation in GenomeStudio. regions prior to validation in GenomeStudio. 560

- 561 **S3 Table. Large, Rare Copy Number Variants Identified in the EBAV Cohort.** Chr., Chromosome on which CNV is located. Start BP, start basepair of CNV. Stop BP, stop basepair of CNV. Type, denotes if a CNV is a
- 562 CNV is located. Start BP, start basepair of CNV. Stop BP, stop basepair of CNV. Type, denotes if a CNV is a duplication (DUP) or deletion (DEL) event. All CNVs were validated in GenomeStudio. duplication (DUP) or deletion (DEL) event. All CNVs were validated in GenomeStudio.

564

565 **S4 Table. Rare CNVs Enriched in EBAV Cohort.** Gene(s), genes intersected by CNV. Chr, chromosome on which each CNV is on. Start BP, start basepair of each CNV. Stop BP, stop basepair of each CNV. Type, denot

566 which each CNV is on. Start BP, start basepair of each CNV. Stop BP, stop basepair of each CNV. Type, denotes if a CNV was a duplication (DUP) or deletion (DEL) event.

a CNV was a duplication (DUP) or deletion (DEL) event.

* Indicates the call was from an unaffected family member. 569

570 **S5 Table. Rare CNVs Enriched in BAVGWAS Cohort.** Gene(s), genes intersected by CNV. Chr, chromosome on which each CNV is on. Start BP, start basepair of each CNV. Stop BP, stop basepair of each CNV. Type, denotes if

a CNV was a duplication (DUP) or deletion (DEL) event.

22q11 22 20742450 21461607 DEL

575 **S5 Table. EBAV CNVs intersecting with Genes of Interest.** Gene/Region, Principal gene or region of interest intersected by CNV. Chr, chromosome on which each CNV is on. Start BP, start basepair of each CNV. Stop BP, 576 intersected by CNV. Chr, chromosome on which each CNV is on. Start BP, start basepair of each CNV. Stop BP,
577 stop basepair of each CNV. Type, denotes if a CNV was a duplication (DUP) or deletion (DEL) event.

577 stop basepair of each CNV. Type, denotes if a CNV was a duplication (DUP) or deletion (DEL) event.
578 * Indicates the call was from an unaffected family member.

578 * Indicates the call was from an unaffected family member.
579 ** Indicates the call was from an affected family member from

** Indicates the call was from an affected family member from a multiplex family.

581 **S7 Table. BAVGWAS CNVs intersecting with Genes of Interest.** Gene/Region, Principal gene or region of interest intersected by CNV. Chr, chromosome on which each CNV is on. Start BP, start basepair of each CNV

582 interest intersected by CNV. Chr, chromosome on which each CNV is on. Start BP, start basepair of each CNV.
583 Stop BP, stop basepair of each CNV. Type, denotes if a CNV was a duplication (DUP) or deletion (DEL) event

Stop BP, stop basepair of each CNV. Type, denotes if a CNV was a duplication (DUP) or deletion (DEL) event.

584

585

586 **S8 Table. Large Genomic Events in BAVGWAS** Chr., Chromosome CNV on which CNV is located. Start BP, start base pair of CNV. Stop BP, stop base pair of CNV. Type, denotes if a CNV is a duplication (DUP) or deletic

587 start base pair of CNV. Stop BP, stop base pair of CNV. Type, denotes if a CNV is a duplication (DUP) or deletion (DEL) event. Description, denotes if the CNV was a mosaic loss of heterozygosity (Mosaic LOH), loss of

588 (DEL) event. Description, denotes if the CNV was a mosaic loss of heterozygosity (Mosaic LOH), loss of heterozygosity (LOH), mosaic (Mosaic), constitutional (constitutional), or trisomy 21 (Trisomy 21) event.

heterozygosity (LOH), mosaic (Mosaic), constitutional (constitutional), or trisomy 21 (Trisomy 21) event.

⁵⁹⁰ 591

PROBAND	GENE	SEGREGATES?	WITH CNV	NO CNV	SEX
BAV064	<i>GATA4</i>	Yes	Father [*] , Paternal	Paternal Grandmother	Female
			Grandfather*		
BAV475	<i>DSCAM</i>	Yes	Sister*	Father	Female
BAV787	CELSR1	Yes	None	Daughter	Female

592 **S9 Table. Pedigree Information for CNVs that Segregated with Disease.** Proband, identification number of proband with CNV intersecting with gene of interest. Gene, gene of interest intersected by CNV. Segregates?,

593 proband with CNV intersecting with gene of interest. Gene, gene of interest intersected by CNV. Segregates?,
594 indicates if the CNV segregated with disease. Family With CNV, family members of proband that were found

594 indicates if the CNV segregated with disease. Family With CNV, family members of proband that were found to
595 have a CNV intersecting with the respective gene. Family Without CNV, family members of proband who were r

595 have a CNV intersecting with the respective gene. Family Without CNV, family members of proband who were not found to have a CNV intersecting with the respective gene. Family members are listed if their genotype was

- 596 found to have a CNV intersecting with the respective gene. Family members are listed if their genotype was available for the study. Sex, sex of the proband.
- 597 available for the study. Sex, sex of the proband.
598 *Indicates family members who also have BAV.
- *Indicates family members who also have BAV.